Pharmaceutical giant Novartis is making a big purchase. The Swiss company is purchasing U.S. Endocyte for $2.1 billion. Endocyte is currently conducting clinical trials for radiopharmaceuticals, which are drugs that help diagnose and target tumors. These radiopharmaceuticals could be used to treat men with metastatic castration-resistant prostate cancer. “Today’s announcement about the proposed acquisition of … Continue reading “Novartis is Buying Endocyte for $2.1 Billion”
Biotech & Pharma
This Startup Can Detect a Dangerous Blood Condition Through Heart Signals
AliveCor, a start-up medical device and artificial intelligence company that sells ECG hardware and software…
AstraZeneca’s Experimental Lupus Treatment Fails to Hit Primary Endpoint
Anifrolumab, AstraZeneca Plc's experimental treatment for lupus, has missed its primary endpoint in a study.…
Insys Therapeutics Skyrockets on FDA Fast Track Designation
Shares of Insys Therapeutics were on the rise in Thursday's trading session after the company…
Gilead Paid $510 Million For This Drug But Sold it For Only $3 Million
It was five years ago that Gilead Sciences Inc. paid $510 million for a deal…
PTC Therapeutics Announces it Will Buy Agilis Biotherapeutics for $200M
It was on Thursday that PTC Therapeutics announced that it plans to acquire five-year old…
Sage Shares Soar After FDA Gives Green Light for This
Shares of Sage Therapeutics were exploding in Tuesday trading after the Food and Drug Administration…
Stryker Makes Takeover Offer for Rival Boston Scientific Corp.
It was an interesting day for medical device makers Stryker and Boston Scientific Corp. While…
Sanofi Responds to Roseanne’s Ambien Tweet with Epic Response
Sanofi, the maker of Ambien, wasn't taking things sitting down when Roseanne Barr blamed her…
FDA Says Teething Medicines Aren’t Safe for Children
This may not be the best news for parents to read who have teething children,…
Amgen Migraine Preventive Drug gets FDA Approval
The Food and Drug Administration has approved Amgen's drug Aimovig for the prevention of migraines.…
Elliott Management Makes Unsolicited Bid to Take Athenahealth Private
Athenahealth shares saw big gains on Monday after it was revealed that hedge fund Elliott…
Acadia Shares Fall After FDA Launches Safety Review on its Parkinson’s Disease Medication
Shares of biotech giant Acadia Pharmaceuticals were deep in the red in Wednesday trading after…
Merck Just Received an Upgrade from Goldman Sachs for This Reason
Shares of Merck were on the rise in Monday trading after the pharmaceutical giant received…
